Provention Bio, Inc. (PRVB): Price and Financial Metrics

Provention Bio, Inc. (PRVB): $24.98

0.75 (+3.10%)

POWR Rating

Component Grades

Momentum

C

Stability

F

Sentiment

Quality

D

Add PRVB to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#326 of 382

in industry

PRVB Price/Volume Stats

Current price $24.98 52-week high $25.00
Prev. close $24.23 52-week low $3.18
Day low $24.98 Volume 9,124,100
Day high $25.00 Avg. volume 2,277,701
50-day MA $18.51 Dividend yield N/A
200-day MA $9.84 Market Cap 2.37B

PRVB Stock Price Chart Interactive Chart >


Provention Bio, Inc. (PRVB) Company Bio


Provention Bio, Inc. operates as a biopharmaceutical company. The Company focuses on development of novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated disease. Provention Bio serves patients in the State of New Jersey.


PRVB Latest News Stream


Event/Time News Detail
Loading, please wait...

PRVB Latest Social Stream


Loading social stream, please wait...

View Full PRVB Social Stream

Latest PRVB News From Around the Web

Below are the latest news stories about PROVENTION BIO INC that investors may wish to consider to help them evaluate PRVB as an investment opportunity.

Sanofi/Provention: innovative diabetes drug is a good fit

US diabetes drugmaker Provention Bio is a case in point. Sanofi has bought it for $2.9bn in cash, more than three times its undisturbed price, in a deal that closed last week. The deal is a good fit for Sanofi, even though boss Paul Hudson pulled back from diabetes research in 2019.

Yahoo | May 1, 2023

Those who invested in Provention Bio (NASDAQ:PRVB) a year ago are up 456%

Active investing isn't easy, but for those that do it, the aim is to find the best companies to buy, and to profit...

Yahoo | April 29, 2023

Earnings Preview: Provention Bio, Inc. (PRVB) Q1 Earnings Expected to Decline

Provention Bio, Inc. (PRVB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | April 27, 2023

Sanofi's $3B Acquisition Of Provention Bio Hits Regulatory Roadblock: FTC Requests More Information

Sanofi SA (NASDAQ: SNY) withdrew and refiled the Premerger Notification and Report Form under the Hart-Scott-Rodino Antitrust Improvements Act “following informal discussions with the staff of the” Federal Trade Commission (FTC) regarding the acquisition of Provention Bio Inc (NASDAQ: PRVB). Sanofi agreed to acquire Provention Bio at $25 per share in a deal valued at $2.9 billion. The agency, it added, needed more time to look at the deal and “information recently provided to them,” Sanofi said

Yahoo | April 11, 2023

Strength Seen in Apellis Pharmaceuticals, Inc. (APLS): Can Its 16.3% Jump Turn into More Strength?

Apellis Pharmaceuticals, Inc. (APLS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Yahoo | April 4, 2023

Read More 'PRVB' Stories Here

PRVB Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year 2.21%
3-year 210.31%
5-year 694.28%
YTD N/A
2023 0.00%
2022 88.08%
2021 -66.82%
2020 13.69%
2019 741.81%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!